Zaltrap (aflibercept) is a type of targeted treatment known as a fusion protein. This treatment is designed to target multiple growth factors involved in cancer and angiogenesis, specifically proteins called VEGF-A, VEGF-B and a related protein called placental growth factor (PlGF).
Zaltrap is approved for use as treatment in second-line therapy in combination with chemotherapy (FOLFIRI) for metastatic bowel cancer.
Is Zaltrap available on the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?
- Zaltrap has been approved by the Therapeutic Goods Administration (TGA) for use in Australia, however, it is not currently listed on the PBS as a subsidised treatment.
Download the Consumer Medicine Information (CMI) for Zaltrap.
